Cadila Pharmaceuticals

Cadila Pharmaceuticals is a multinational research based pharmaceutical group in India with more than 6 decades of experience. Company's integrated operations covers entire gamut from manufacturing products ranging from API's-Intermediates, finished formulations, OTC-Food Supplements, Biotechnology Products and pharmaceutical Machinery. Cadila Pharmaceuticals manufacturing facilities are approved by most stringent International bodies like WHO-GMP, UK-MHRA, USFDA-API, TGA-Australia, and AIFA-Italy. International operation of Cadila Pharmaceuticals is spread across 58 countries including Americas, Japan, Asia, CIS and Africa.[1]

Cadila Pharmaceuticals Limited
Type
Private company
IndustryPharmaceuticals
Founded1951
FounderIndravadan Modi
Headquarters
Ahmedabad, Gujarat
,
India
Key people
Dr. Rajiv Modi
(Chairman and Managing Director)
ProductsAPIs, Generic drugs
ServicesContract Research, Contract Manufacturing
Number of employees
8000
SubsidiariesIRM Ltd
Websitewww.cadilapharma.com

History

Cadila Laboratories

In 1951 Indravadan A Modi had quit his job as a chemist in a Mumbai firm to start Cadila Laboratories with childhood friend Ramanbhai Patel. The company that started in a rented bungalow with a capital of Rs 25,000 and achieved a turnover of around Rs 1.25 lakh in its first year of operation had come a long way.[2]

1995: Demerger of Cadila Laboratories

The Modi and Patel families decided to split the business in 1995, two entities were formed - Cadila Pharmaceuticals Ltd (owned and controlled by Shri. I A Modi and his son Dr. Rajiv Modi) and Cadila Healthcare (owned by Shri. Ramanbhai Patel and his son Pankaj Patel family). Rajiv Modi and I A Modi worked closely to run Cadila Pharma, now considered one of the largest privately-held pharma companies in the country, with revenues of around Rs 1200 crore.[2]

Operations

Cadila Pharmaceuticals has its formulation manufacturing facilities at Dholka, Gujarat (India); Samba, Jammu (India) and at Addis Ababa (Ethiopia) and 2 API manufacturing facilities are located at Ankleshwar, Gujarat. The manufacturing facility at Dholka and the API unit at Ankleshwar in Gujarat are USFDA-certified; the overseas manufacturing facility at Ethiopia is the WHO - cGMP compliant facility.[3]

Research

Cadila Pharmaceuticals has established a dedicated R&D facility, spread over 1,05,000 sq. ft. area at Dholka, Gujarat, India which is manned by 300 scientists.

The company has five IND dossiers filed with the USFDA for pulmonary tuberculosis, lung cancer, prostate cancer, bladder cancer and melanoma. The company has submitted ten ANDAs.[4] Cadila Pharmaceuticals has connections with various institutions for research; Department of Biotechnology, UDSC, New Delhi; IISc, Bangalore; Lala Ram Sarup Institute of TB & Respiratory diseases, New Delhi; RRL, Jammu; CSIR, New Delhi; CDRI, Lucknow; Advanced Transfusion Medicine Research Foundation, Ahmedabad; National Institute of Immunology, New Delhi; Institute of Microbial Technology, Chandigarh; Talwar Research Foundation, New Delhi and Trieste, Italy.[5]

Products and services

Cadila Pharmaceuticals is the only Indian manufacturer of natural Streptokinase and Hyaluronic Acid products. The company was also the first in the world to introduce Rabeprazole in IV form – ‘Rabeloc’.[6] In 2009, the world’s first boosted-Rifampicin fixed-dose combination for the treatment of Tuberculosis – ‘Risorine’[7] and world's first drug combination for prevention of Cardiovascular Diseases – ‘Polycap’ were introduced by Cadila Pharmaceuticals.[8] For the patients suffering from Non Small Cell Lung Cancer (NSCLC), company has recently introduced ‘Mycidac-C’ - first in the class active immunotherapy as well as drug targeting Desmocollin.[9] Some of the top brands of the company are Aciloc, Envas, Calcirol, Haem Up, Vasograin, Tricort, Fludac, Rabiloc, Trigan-D and Mycobutol.

Alliances

In 2019, Cadila Pharmaceuticals formed a partnership with Norwegian start-up, Serca Pharmaceuticals to develop new treatment for heart patients.[10]

Awards and Recognition

Most Trusted Companies of 2008, Sara Media and Zee Business[11]

WorldStar Packaging Award, 2018[12]

TISS LeapVault CLO Award, 2019[13]

Observenow Future of Workplace Award, 2019[14]

References

  1. "Cadila Pharmaceuticals Ltd". CPhI Worldwide - Uniting the Pharmaceutical Industry. 13 September 2018.
  2. Das, Sohini (28 January 2014). "Carrying the legacy forward: Rajiv Modi" via Business Standard.
  3. Financial Express 28 January 2013
  4. "Welcome to India in Business". www.indiainbusiness.nic.in.
  5. "Cadila Pharma".
  6. Bureau, Our Regional (16 July 2004). "Cadila Pharma unveils acidity drug in IV form" via Business Standard.
  7. "Cadila launches new drug for TB treatment". dna. 31 October 2009.
  8. "Cadila Pharmaceuticals launches Polycap, which reduces cardiovascular and stroke risk substantially". The Financial Express. 2 April 2009.
  9. "Economic Times 21 November 2013".
  10. Bureau, Our. "Cadila Pharma inks pact with Norwegian start-up to develop new treatment for heart patients". @businessline. Retrieved 11 January 2019.
  11. "Indravadan A Modi: The medicine man of India". DeshGujarat. 26 November 2012. Retrieved 16 October 2019.
  12. "Calcirol Softgel | Worldstar". www.worldstar.org. Retrieved 16 October 2019.
  13. "Cadila Pharma bags TISS LeapVault CLO awards in two categories". Express Pharma. 9 August 2019. Retrieved 16 October 2019.
  14. Bureau, The Pharma Times News (14 September 2019). "Cadila Pharma wins 'ObserveNow Future of Workplace Award'". The Pharma Times | Pharma & Health Care News Portal. Retrieved 16 October 2019.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.